Clinical Evaluation of a Lead Mobilization Test Using the Chelating Agent Dimercaptosuccinic Acid

Hoet, Peter; Buchet, Jean‐Pierre; Decerf, Laurence; Lavalleye, Benoît; Haufroid, Vincent; Lison, Dominique

doi:10.1373/clinchem.2005.051128

Cited by 22 publications

(11 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DMSA safety and efficacy has been documented in children and adults for many years [10][11][12][13].…”

Section: Discussionmentioning

confidence: 99%

Thrombocytosis secondary to chronic lead poisoning

Momen

2010

Platelets

View full text Add to dashboard Cite

We report a case of total hyperpigmentation of the skin, severe itching, muscle weakness and thrombocytosis. Laboratory investigation showed white blood cell (WBC) 8.2 x 10(6)/L, Hb 125 g/L, platelets 1221 x 10(6)/L and urinary lead after DMSA mobilization test 2684 mcg/g creatinine (normal <5). Chelation therapy with DMSA resulted in complete recovery of the hyperpigmentation, itching and thrombocytosis. Lead poisoning should be considered in the differential diagnosis of obscured thrombocytosis.

show abstract

“…DMSA safety and efficacy has been documented in children and adults for many years [10][11][12][13].…”

Section: Discussionmentioning

confidence: 99%

Thrombocytosis secondary to chronic lead poisoning

Momen

2010

Platelets

View full text Add to dashboard Cite

show abstract

“…One of the most effective methods to evaluate net retention, or at least the biologically readily available metal load, is to compare the levels of metals in urine before and after the administration of a pharmaceutical chelating agent such as CaNa 2 EDTA, DMSA, or DMPS [98]. Variously known as “mobilization,” “chelation challenge,” or a “provocation” test, this procedure is not universally accepted as standard of care.…”

Section: Pharmaceutical Chelatorsmentioning

confidence: 99%

Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review

Sears

2013

The Scientific World Journal

209

141

View full text Add to dashboard Cite

Toxic metals such as arsenic, cadmium, lead, and mercury are ubiquitous, have no beneficial role in human homeostasis, and contribute to noncommunicable chronic diseases. While novel drug targets for chronic disease are eagerly sought, potentially helpful agents that aid in detoxification of toxic elements, chelators, have largely been restricted to overt acute poisoning. Chelation, that is multiple coordination bonds between organic molecules and metals, is very common in the body and at the heart of enzymes with a metal cofactor such as copper or zinc. Peptides glutathione and metallothionein chelate both essential and toxic elements as they are sequestered, transported, and excreted. Enhancing natural chelation detoxification pathways, as well as use of pharmaceutical chelators against heavy metals are reviewed. Historical adverse outcomes with chelators, lessons learned in the art of using them, and successes using chelation to ameliorate renal, cardiovascular, and neurological conditions highlight the need for renewed attention to simple, safe, inexpensive interventions that offer potential to stem the tide of debilitating, expensive chronic disease.

show abstract

“…No threshold for toxic effects of lead has been identified [2][3][4]. At lower lead levels, there may be no obvious clinical manifestations, but there might be adverse effects on the central nervous, renal, hematopoietic, and skeletal systems [2,5].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Allicin for the Treatment of Experimentally Induced Subacute Lead Poisoning in Sheep

Najarnezhad

Aslani

Balali-Mood

2008

Biol Trace Elem Res

View full text Add to dashboard Cite

Garlic (Allium sativum) is known to reduce lead toxicity in some species of animals. The objective of this study was to evaluate the efficacy of allicin, one of the most active components of garlic, in the treatment of subacute lead intoxication in sheep. Nine female sheep weighing 25-29 kg orally received a daily dose of 80 mg/kg body weight of lead acetate for 5 days. The animals were then assigned into two groups. Group 1 did not receive any further treatment and was used as the control group and group 2 was treated orally by 2.7 mg/kg body weight of allicin twice daily for 7 days. Within one day following allicin treatment, group 2 blood lead levels were significantly lower than that in group 1 (mean of 616.9 microg/l and 290.02 microg/l, respectively; P < 0.05). Also, allicin treatment significantly reduced kidney lead content and considerably reduced bone and ovary lead contents. These results suggest that allicin might have some therapeutic effects on lead poisoning.

show abstract

Clinical Evaluation of a Lead Mobilization Test Using the Chelating Agent Dimercaptosuccinic Acid

Cited by 22 publications

References 57 publications

Thrombocytosis secondary to chronic lead poisoning

Thrombocytosis secondary to chronic lead poisoning

Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review

Evaluation of Allicin for the Treatment of Experimentally Induced Subacute Lead Poisoning in Sheep

Contact Info

Product

Resources

About